Wayne State University (WSU) has been a participating institution in the Southwest Oncology Group (SWOG) for over 15 years. Membership within our institution continues to grow, thereby enhancing our clinical and laboratory research efforts for the group. WSU's overall objective is to strive towards significant advances in the treatment of cancer patients by designing, conducting, and participating in SWOG clinical trials. We believe a cooperative group approach will allow for the necessary patient population needed to answer the various questions regarding the treatment and control of cancer. We, as a multimodality institution, believe that collaborative efforts from the various disciplines (i.e., Hematology-Oncology, Radiation Oncology, Surgery, Pathology, GYN-ONC and Experimental Therapeutics) allows us to further enhance our abilities to develop new and innovative studies. Through CCOP, our community physicians are allowed access to clinical trials which are confined to an institutional setting. Dr. Laurence Baker continues to provide administrative assistance to SWOG as the Associate Chairman of the Group. He encourages faculty members to actively participate in the various disease committees. To date, 24 WSU members are currently serving on 60 committees. There are 12 SWOG studies in which a WSU member was listed as the primary coordinator; as co-coordinators, there are 20. Our patient registration increased from 131 in 1985 to 156 in 1986. Our recent successes in recruiting Drs. M. Valdivieso, L. Heilbrun, L. Sensenbrenner, D. Weaver, and G. Deppe into our SWOG program promises even greater scientific and patient accrual participation.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA014028-19
Application #
3556243
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1978-01-01
Project End
1992-12-31
Budget Start
1992-01-01
Budget End
1992-12-31
Support Year
19
Fiscal Year
1992
Total Cost
Indirect Cost
Name
Wayne State University
Department
Type
Schools of Medicine
DUNS #
City
Detroit
State
MI
Country
United States
Zip Code
48202
Moots, Paul L; O'Neill, Anne; Londer, Harold et al. (2018) Preradiation Chemotherapy for Adult High-risk Medulloblastoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4397). Am J Clin Oncol 41:588-594
Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585
Agarwala, Sanjiv S; Lee, Sandra J; Yip, Waiki et al. (2017) Phase III Randomized Study of 4 Weeks of High-Dose Interferon-?-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Gro J Clin Oncol 35:885-892
Wozniak, Antoinette J; Moon, James; Thomas Jr, Charles R et al. (2015) A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Combination of Bevacizumab (NSC-704865) in Patients With Inoperable Locally Advanced Stage III Non-Small-Cell Lung Cancer: SWOG S0533. Clin Lung Cancer 16:340-7
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Othus, Megan; Appelbaum, Frederick R; Petersdorf, Stephen H et al. (2015) Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy. Biol Blood Marrow Transplant 21:559-64
Ou, Sai-Hong Ignatius; Moon, James; Garland, Linda L et al. (2015) SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM). J Thorac Oncol 10:387-91
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Gonsalves, Wilson I; Mahoney, Michelle R; Sargent, Daniel J et al. (2014) Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147. J Natl Cancer Inst 106:
Gralow, Julie R; Barlow, William E; Lew, Danika et al. (2014) A phase II study of docetaxel and vinorelbine plus filgrastim for HER-2 negative, stage IV breast cancer: SWOG S0102. Breast Cancer Res Treat 143:351-8

Showing the most recent 10 out of 215 publications